Impact of dupilumab on medical readiness in a military population

Gregory S Hill; Michael W Noller; Cristianah O Olubajo; Anthony M Tolisano; Charles A Riley; Jakob L Fischer

doi:10.1002/alr.23300

Impact of dupilumab on medical readiness in a military population

Int Forum Allergy Rhinol. 2024 May;14(5):999-1001. doi: 10.1002/alr.23300. Epub 2023 Nov 13.

Authors

Gregory S Hill¹, Michael W Noller¹, Cristianah O Olubajo², Anthony M Tolisano^{1

3}, Charles A Riley^{1

3}, Jakob L Fischer^{3

4}

Affiliations

¹ Department of Otolaryngology-Head & Neck Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
² School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
³ Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
⁴ Department of Otolaryngology-Head and Neck Surgery, University of California, Los Angeles, Los Angeles, California, USA.

PMID: 37955607
DOI: 10.1002/alr.23300

Abstract

Military servicemembers reported high satisfaction rates of dupilumab treatment for CRSwNP. Some service members fear that dupilumab treatment may limit their career progression. Updated guidelines are needed for servicemembers to make decisions regarding dupilumab.

Keywords: chronic rhinosinusitis; immunotherapy; quality of life.

MeSH terms

Adult
Antibodies, Monoclonal, Humanized* / therapeutic use
Female
Humans
Male
Military Personnel*
Patient Satisfaction
Rhinitis, Allergic / drug therapy

Substances

dupilumab
Antibodies, Monoclonal, Humanized